{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:18:09Z","timestamp":1782278289017,"version":"3.54.5"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021981","name":"Roche Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021981","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.cllc.2025.01.011","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T21:45:50Z","timestamp":1738187150000},"page":"244-252.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Atezolizumab in Chinese Patients With Advanced Thymic Carcinoma: A Multicenter, Single-Arm Phase 2 Study"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-7262","authenticated-orcid":false,"given":"Shun","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunxu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhou","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2025.01.011_bib0001","first-page":"1170","article-title":"Current treatment approaches for thymic epithelial tumors","volume":"13","author":"Tartarone","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.cllc.2025.01.011_bib0002","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/1759-7714.14847","article-title":"Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors","volume":"14","author":"Xu","year":"2023","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2025.01.011_bib0003","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1200\/JCO.2011.36.0487","article-title":"Thymic malignancies: from clinical management to targeted therapies","volume":"29","author":"Kelly","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.01.011_bib0004","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2025.01.011_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107557","article-title":"Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: results from the multicenter, phase 2 REMORA trial","volume":"191","author":"Niho","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2025.01.011_bib0006","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.01.011_bib0007","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12943-023-01772-4","article-title":"Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives","volume":"22","author":"Ao","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.cllc.2025.01.011_bib0008","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2147\/DDDT.S188893","article-title":"Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis","volume":"13","author":"Tie","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.cllc.2025.01.011_bib0009","first-page":"395","article-title":"[Chinese guideline for clinical diagnosis and treatment of thymic epithelial tumors (2021 Edition)]","volume":"43","year":"2021","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.cllc.2025.01.011_bib0010","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.01.011_bib0011","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2025.01.011_bib0012","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2025.01.011_bib0013","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(22)00542-3","article-title":"Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Conforti","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2025.01.011_bib0014","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.cllc.2023.05.004","article-title":"Study design and rationale for marble study: a phase II trial of atezolizumab (MPDL3280A) plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (JTD2101)","volume":"24","author":"Asao","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2025.01.011_bib0015","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1016\/j.cllc.2021.07.008","article-title":"PECATI: a multicentric, open-label, single-arm phase II study to evaluate the efficacy and safety of pembrolizumab and lenvatinib in pretreated B3-thymoma and thymic carcinoma patients","volume":"23","author":"Remon","year":"2022","journal-title":"Clin Lung Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T11:12:42Z","timestamp":1749294762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425000221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1525730425000221"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.01.011","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Atezolizumab in Chinese Patients With Advanced Thymic Carcinoma: A Multicenter, Single-Arm Phase 2 Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}